Penserra Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Penserra Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,676	Closed	-$48K	–	1040
2025 Q2	$48K	Buy	+1,676	New	+$51.8K	﹤0.01%	767
2021 Q4	–	Sell	-885	Closed	-$18K	–	1404
2021 Q3	$18K	Buy	885 +30	+4%	+$628	﹤0.01%	1260
2021 Q2	$16K	Buy	855 +110	+15%	+$1.93K	﹤0.01%	1196
2021 Q1	$11K	Sell	745 -10	-1%	-$155	﹤0.01%	1022
2020 Q4	$10K	Buy	+755	New	+$10.5K	﹤0.01%	923

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Penserra Capital Management's CRNX Position: Q3 2025 in Review

Penserra Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 1,676 shares — an estimated $48K sold.

Penserra Capital Management first reported a position in CRNX in Q4 2020 and held it in 5 quarters. The position peaked at $48K in Q2 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

Penserra Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Penserra Capital Management sold 1,676 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $48K.
Penserra Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Penserra Capital Management's Crinetics Pharmaceuticals position peaked at $48K in Q2 2025.
225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Penserra Capital Management's 13F filing for Q3 2025, filed 4 Nov 2025.